Amit Saha, MD
Colon & Rectal Surgery · Oklahoma City, OKNPI 1598720013
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by TELA Bio, Inc. at 34.1% of the total. Reporting peaked in 2021 at $1,907 and has fallen 53.2% since, to $892 in 2025.
Across 250 payments — averaging $34.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TELA Bio, Inc.$3K
- Medtronic$1K
- TAS Medical, Inc.$778
- Organogenesis Inc.$567
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$509
- Takeda Pharmaceuticals U.S.A., Inc.$503
- plus $2K from 27 others
What the payments were for
- Food & beverage$8,716100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TELA Bio, Inc. | 29 | $2,970 |
| Medtronic(2 entities) | 24 | $1,166 |
| TAS Medical, Inc. | 4 | $778 |
| Organogenesis Inc. | 24 | $567 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 40 | $509 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $503 |
| Bristol Myers Squibb | 42 | $466 |
| Merck | 23 | $339 |
| Abiomed | 2 | $217 |
| Intuitive Surgical | 3 | $175 |
| Tenex Health Inc. | 1 | $154 |
| Vifor Pharma, Inc. | 1 | $120 |
| Acera Surgical, Inc. | 5 | $114 |
| Biotronik Inc. | 1 | $66 |
| Boston Scientific | 2 | $51 |
| AstraZeneca | 3 | $51 |
| Daiichi Sankyo Inc. | 3 | $50 |
| AbbVie(2 entities) | 2 | $48 |
| Pacira Pharmaceuticals Incorporated | 2 | $44 |
| Axonics, Inc. | 1 | $38 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Ambu Inc. | 1 | $32 |
| Smith+Nephew | 2 | $30 |
| Davol Inc. | 2 | $30 |
| Shire North American Group Inc | 1 | $23 |
| THD America, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| KCI USA, Inc. | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Convatec Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $17 |
| Baudax Bio Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,716 in reported general payments places this provider in the 85th percentile of 21 colon & rectal surgery providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DificidFidaxomicin | 16 | $81,253 |
| Mesalamine | 71 | $23,612 |
| MovantikNaloxegol Oxalate | 47 | $23,114 |
| Colestipol Hcl | 139 | $5,261 |
| Dexlansoprazole DrDexlansoprazole | 11 | $3,439 |
| Vancomycin Hcl | 36 | $3,053 |
| Pantoprazole Sodium | 150 | $1,782 |
| CeftriaxoneCeftriaxone Sodium | 11 | $1,600 |
| Dicyclomine Hcl | 58 | $1,135 |
| Balsalazide Disodium | 13 | $1,126 |
| Budesonide DrBudesonide | 11 | $1,124 |
| Metronidazole | 185 | $959 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 89 | $852 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 59 | $768 |
| ConstuloseLactulose | 25 | $712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckDificid | $339 | $81,25316 claims |
| Redhill Biopharma Inc.Movantik | $17 | $23,11447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 21 colon & rectal surgery providers in Oklahoma.
Other colon & rectal surgery in Oklahoma City
- William MustainOklahoma City$130K
- Hani BaradiOklahoma City$23K
- Vicente ArcosOklahoma City$8K
- Dominykas BurneikisOklahoma City$4K
- Gary DunnOklahoma City$3K
- Stephen MahoneyOklahoma City$2K
- Chris DavisOklahoma City$155
- Rodney ClinganTulsa$10K
- Rahal KahandaNorman$9K
- Kaitlin DomekTulsa$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.